ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

3D Systems ($DDD) Forms Systemic Bio to Accelerate Drug Discovery and Development

Green Stock News LLC
 

 

September 9, 2022 – TheNewswire - 3D Systems (DDD) has announced the formation of a new wholly owned company named Systemic Bio. The new biotech company will focus on the application of advanced bio-printing technologies for pharmaceutical drug discovery and development. 

 

The company says that Systemic Bio will leverage its breakthrough production-level bioprinting technology to create extremely precise vascularized organ models using biomaterials and human cells. These proprietary organs-on-chips can be manufactured reproducibly in large quantities and then perfused with desired drug compounds to study drug metabolism and the effects on healthy or diseased tissue at early stages of new pharmaceutical drug development. 

 

The ability to accurately simulate human response to an experimental drug in the laboratory, early in the development process, will offer the potential to significantly reduce both high costs and extended timelines required for pharmaceutical companies to bring new drugs to market. Additionally, the company says that this approach could eventually reduce or even eliminate the need for animal testing as a precursor to full-scale human trials for new drug development.

 

Dr. Jeffrey Graves, President and CEO of 3D Systems stated: “I am pleased and inspired by the progress we continue to make in the emerging field of regenerative medicine. The complexity and precision that we have now demonstrated using biocompatible materials and our most advanced production bioprinting platform technology is truly groundbreaking, opening a host of new applications ranging from the laboratory to replacement organs within the human body.”

 

3D Systems says that it will provide $15 million in seed funding to demonstrate efficacy of the technology and associated business model. The company is targeting revenues for Systemic Bio to approach $100 million annually within five years.


Shares of 3D Systems trade on the NYSE under the ticker symbol DDD. For more information visit www.greenstocknews.com

 

Disclaimer

 

This content is not financial advice and is for information, education and entertainment purposes only. Green Stock News is not responsible for any losses related to the financial decisions made by you. Video content and other materials including web content are based on data obtained from sources we believe to be reliable but are not guaranteed as to accuracy and are not purported to be complete. As such, the information should not be construed as advice designed to meet the particular investment needs of any investor. Green Stock News is not responsible for any gains or losses that result from the opinions expressed in this video or materials that it publishes electronically.

 

View original video news clips here: https://greenstocknews.com/green-stock-newswire 

  

Copyright (c) 2022 TheNewswire - All rights reserved.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.